MCID: SML001
MIFTS: 58

Small Cell Carcinoma

Categories: Cancer diseases, Respiratory diseases, Genetic diseases, Skin diseases, Rare diseases

Aliases & Classifications for Small Cell Carcinoma

MalaCards integrated aliases for Small Cell Carcinoma:

Name: Small Cell Carcinoma 12 15
Small Cell Carcinoma, Intermediate Cell 12 73
Small Cell Carcinoma - Intermediate Cell 12
Intermediate Cell Small Cell Carcinoma 12
Small Cell Carcinoma of Lung 73
Carcinoma, Small Cell 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0050685
NCIt 50 C4099
SNOMED-CT 68 189557009 5958006
UMLS 73 C0334239

Summaries for Small Cell Carcinoma

Disease Ontology : 12 A carcinoma that is an undifferentiated neoplasm composed of primitive-appearing cells.

MalaCards based summary : Small Cell Carcinoma, also known as small cell carcinoma, intermediate cell, is related to lung combined type small cell carcinoma and ureter small cell carcinoma. An important gene associated with Small Cell Carcinoma is ENO2 (Enolase 2), and among its related pathways/superpathways are Gastric cancer and Downstream signaling events of B Cell Receptor (BCR). The drugs Etoposide and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and prostate, and related phenotypes are Decreased viability in esophageal squamous lineage and cellular

Related Diseases for Small Cell Carcinoma

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1 Basal Cell Carcinoma 2
Basal Cell Carcinoma 3 Basal Cell Carcinoma 4
Basal Cell Carcinoma 5 Basal Cell Carcinoma 6
Basal Cell Carcinoma 7 Cell Type Cancer
Cell Type Benign Neoplasm Basal Cell Carcinoma
Large Cell Carcinoma Basal Cell Carcinoma, Multiple

Diseases related to Small Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 436)
# Related Disease Score Top Affiliating Genes
1 lung combined type small cell carcinoma 34.8 NCAM1 SYP
2 ureter small cell carcinoma 34.6 CHGA ENO2 SYP
3 gallbladder small cell carcinoma 34.0 CHGA ENO2 NCAM1 SYP
4 prostate small cell carcinoma 33.6 ASCL1 ENO2 KLK3
5 gastric small cell carcinoma 33.5 CHGA ENO2 NCAM1 PTPRC SYP
6 cervix small cell carcinoma 33.5 CHGA ENO2 NCAM1 SYP TP53
7 small cell carcinoma of the bladder 33.3 CHGA ENO2 KRT20 KRT7 NKX2-1 SYP
8 endometrial small cell carcinoma 32.2 ENO2 KIT NCAM1 PDGFRA PTPRC SYP
9 pulmonary large cell neuroendocrine carcinoma 30.9 CHGA ENO2 SYP
10 sex cord-gonadal stromal tumor 30.4 ENO2 KRT7 SYP
11 spindle cell carcinoma 30.4 ENO2 KRT7 SYP
12 adenocarcinoma 30.4 EGFR KIT PTEN TP53
13 carcinoid syndrome 30.3 CALCA CHGA ENO2 SYP
14 ovarian mucinous neoplasm 30.3 ENO2 KRT20 KRT7 SYP
15 mucinous cystadenocarcinoma 30.1 KRT20 KRT7 PTPRC
16 atypical teratoid rhabdoid tumor 30.1 SMARCA4 SYP TP53
17 endocervical adenocarcinoma 30.0 KRT20 KRT7 TP53
18 tubular adenocarcinoma 30.0 CHGA EGFR KRT20
19 follicular adenoma 30.0 CALCA NKX2-1 PTEN
20 achalasia 30.0 ENO2 KIT TP53
21 merkel cell carcinoma 29.9 CHGA ENO2 KIT KRT20 KRT7 NCAM1
22 dermoid cyst 29.8 CHGA KIT KRT20 KRT7
23 li-fraumeni syndrome 29.7 EGFR PTEN TP53
24 basaloid squamous cell carcinoma 29.6 EGFR ENO2 KRT7 SYP TP53
25 adenosquamous carcinoma 29.4 EGFR KRT7 NKX2-1 TP53
26 cervical adenocarcinoma 29.4 EGFR KRT20 KRT7 TP53
27 lung cancer susceptibility 3 29.4 EGFR KRT20 KRT7 NKX2-1 TP53
28 cystic teratoma 29.3 ENO2 KRT20 KRT7 NKX2-1 SYP TP53
29 teratoma 29.3 ENO2 KIT KRT7 NKX2-1 SYP TP53
30 pulmonary blastoma 29.2 CHGA EGFR NKX2-1 SYP TP53
31 bladder urothelial carcinoma 29.1 KLK3 KRT20 KRT7 TP53
32 rhabdomyosarcoma 29.0 ENO2 PDGFRA PTPRC TP53
33 adenoid cystic carcinoma 29.0 KIT KRT20 KRT7 NCAM1 PTEN TP53
34 renal cell carcinoma, nonpapillary 29.0 EGFR KIT KRT20 KRT7 NKX2-1
35 large cell carcinoma 28.9 CHGA EGFR ENO2 KRT7 NCAM1 NKX2-1
36 pleomorphic carcinoma 28.9 EGFR KIT KRT7 NKX2-1 TP53
37 transitional cell carcinoma 28.9 EGFR ENO2 KRT20 KRT7 PTEN TP53
38 prostate cancer 28.9 CHGA EGFR ENO2 KLK3 PTEN TMPRSS2
39 glioblastoma multiforme 28.7 EGFR PDGFRA PTEN TP53
40 suppression of tumorigenicity 12 28.5 CHGA KLK3 PTEN TMPRSS2 TP53
41 chordoma 28.4 EGFR KRT7 PDGFRA PTEN TP53
42 small cell cancer of the lung 28.3 ASCL1 CALCA CHGA EGFR ENO2 KIT
43 breast adenocarcinoma 28.0 CALCA EGFR TP53
44 cholangiocarcinoma 27.9 EGFR KIT KRT20 KRT7 NCAM1 PTEN
45 large cell neuroendocrine carcinoma 27.4 ASCL1 CHGA EGFR ENO2 KIT KRT20
46 neuroendocrine tumor 27.2 ASCL1 CALCA CHGA ENO2 KRT20 KRT7
47 lung cancer 26.6 ASCL1 CHGA EGFR ENO2 KIT KRT7
48 ovarian small cell carcinoma 12.5
49 laryngeal small cell carcinoma 12.2
50 thymus small cell carcinoma 12.2

Graphical network of the top 20 diseases related to Small Cell Carcinoma:



Diseases related to Small Cell Carcinoma

Symptoms & Phenotypes for Small Cell Carcinoma

GenomeRNAi Phenotypes related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.36 ASCL1 CHGA KIT KLK3 KRT7 NKX2-1

MGI Mouse Phenotypes related to Small Cell Carcinoma:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.3 ENO2 ASCL1 KIT KRT7 NCAM1 EGFR
2 growth/size/body region MP:0005378 10.23 EGFR ENO2 ASCL1 CHGA KIT TMPRSS2
3 endocrine/exocrine gland MP:0005379 10.22 NKX2-1 ASCL1 KIT CHGA EGFR TP53
4 mortality/aging MP:0010768 10.21 EGFR ASCL1 CHGA KIT NCAM1 TMPRSS2
5 nervous system MP:0003631 10.15 NKX2-1 ENO2 ASCL1 KIT NCAM1 EGFR
6 digestive/alimentary MP:0005381 10.1 EGFR KIT TP53 PTEN NKX2-1 PTPRC
7 neoplasm MP:0002006 10.06 NKX2-1 KIT EGFR TP53 TMPRSS2 PTPRC
8 craniofacial MP:0005382 10.05 EGFR ENO2 ASCL1 KIT TP53 PDGFRA
9 normal MP:0002873 10 NKX2-1 ASCL1 KIT EGFR TP53 TMPRSS2
10 no phenotypic analysis MP:0003012 9.92 EGFR ASCL1 CHGA KIT TP53 NKX2-1
11 pigmentation MP:0001186 9.63 ASCL1 KIT EGFR TP53 PTEN PDGFRA
12 renal/urinary system MP:0005367 9.61 KIT CHGA KRT7 EGFR TP53 PTPRC
13 respiratory system MP:0005388 9.36 NKX2-1 ENO2 ASCL1 KIT EGFR TP53

Drugs & Therapeutics for Small Cell Carcinoma

Drugs for Small Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 413)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
3
Irinotecan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 97682-44-5, 100286-90-6 60838
4
Nicotine Approved Phase 4,Phase 3,Phase 1,Not Applicable 54-11-5 942 89594
5
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
6
Bupropion Approved Phase 4,Phase 3,Phase 2 34841-39-9, 34911-55-2 444
7
Gefitinib Approved, Investigational Phase 4,Phase 2,Not Applicable 184475-35-2 123631
8
Camptothecin Experimental Phase 4,Phase 3,Phase 2,Phase 1 7689-03-4
9 topoisomerase I inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
10 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Central Nervous System Stimulants Phase 4,Phase 3,Phase 1,Not Applicable
15 Cholinergic Agents Phase 4,Phase 3,Phase 1,Not Applicable
16 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
18 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 3,Phase 2
19 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
20 Nicotinic Agonists Phase 4,Phase 3,Phase 1,Not Applicable
21 Dopamine Agents Phase 4,Phase 3,Phase 2
22 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2
23 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Antidepressive Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
25 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 2
26 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
27 Psychotropic Drugs Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
28 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
30
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
31
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
32
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
33
Dacarbazine Approved, Investigational Phase 2, Phase 3,Phase 1 4342-03-4 5351166
34
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
35
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
36
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
37
Heparin Approved, Investigational Phase 3,Phase 2 9005-49-6 772 46507594
38
Mesna Approved, Investigational Phase 3 3375-50-6 598
39
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 119413-54-6, 123948-87-8 60700
40
Temozolomide Approved, Investigational Phase 2, Phase 3,Phase 1 85622-93-1 5394
41
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
42
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
43
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
44
Vinorelbine Approved, Investigational Phase 3,Phase 1,Phase 2 71486-22-1 60780 44424639
45
Dalteparin Approved Phase 3 9005-49-6
46
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
47
Isotretinoin Approved Phase 3,Phase 2 4759-48-2 5538 5282379
48
Zoledronic acid Approved Phase 3,Phase 2 118072-93-8 68740
49
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
50
Ofloxacin Approved Phase 3 82419-36-1 4583

Interventional clinical trials:

(show top 50) (show all 803)
# Name Status NCT ID Phase Drugs
1 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
2 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
3 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer Recruiting NCT02348450 Phase 4 Irinotecan;Etoposide;Cisplatin
4 the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer) Not yet recruiting NCT03264794 Phase 4 Gefitinib Tab (CTTQ),First medication;Gefitinib Tab (CTTQ),From the 8th day of trial;Gefitinib tablets (Yi Ruisha),First medication;Gefitinib Tab 250 MG(CTTQ),From the 8th day of trial.
5 Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy Suspended NCT01720901 Phase 4 Icotinib
6 STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study Unknown status NCT00526396 Phase 3 cisplatin;etoposide;cisplatin;etoposide
7 Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient Unknown status NCT00826644 Phase 3 Belotecan/Cisplatin;Etoposide/Cisplatin
8 Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer Unknown status NCT00003606 Phase 3 cisplatin;cyclophosphamide;epirubicin hydrochloride;etoposide
9 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Small Cell Lung Cancer Unknown status NCT00002858 Phase 3 cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide
10 Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer Unknown status NCT00003696 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;paclitaxel
11 Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer Unknown status NCT00011921 Phase 3 carboplatin;epirubicin hydrochloride;etoposide;etoposide phosphate;ifosfamide;paclitaxel
12 Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer Unknown status NCT02772107 Phase 2, Phase 3 Temozolomide;first-line chemotherapy
13 Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study) Unknown status NCT01555710 Phase 3 Carboplatin;Palifosfamide-tris;Etoposide;Carboplatin
14 Study of Picoplatin Efficacy After Relapse Unknown status NCT00465491 Phase 3 picoplatin
15 A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage Unknown status NCT00168896 Phase 2, Phase 3 Carboplatin plus Irinotecan vs Carboplatin plus Etoposide
16 A Prospective Randomized Study Comparing the Target Volume for Limited-stage Small Cell Lung Cancer Unknown status NCT01731548 Phase 2, Phase 3
17 SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013 Unknown status NCT02738346 Phase 3 Carboplatin;Etoposide;Topotecan
18 Dalteparin in Preventing Blood Clots in Patients With Lung Cancer Unknown status NCT00519805 Phase 3 dalteparin
19 A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer Completed NCT00717938 Phase 3 cisplatinum or carboplatin and e.g.etoposide.;cisplatinum or carboplatin and e.g.etoposide+enoxaparin
20 Bevacizumab in Extensive Small Cell Lung Cancer Completed NCT00930891 Phase 2, Phase 3 Standard Chemotherapy (PCDE or PE);Experimental Treatment (PCDE or PE + bevacizumab);Prerandomization Chemotherapy (PCDE or PE)
21 AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy Completed NCT00547651 Phase 3 Amrubicin;Topotecan
22 Early Versus Late Concurrent Chemoradiation for Limited Stage Small-cell Lung Cancer Completed NCT01125995 Phase 3
23 Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone Completed NCT01450761 Phase 3 Etoposide;Cisplatin;Carboplatin
24 Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer Completed NCT00003011 Phase 3 marimastat;Placebo
25 A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa Completed NCT00119613 Phase 3 placebo;darbepoetin alfa
26 Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults Completed NCT00043927 Phase 3 topotecan/cisplatin;etoposide/cisplatin
27 Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer Completed NCT00143455 Phase 3 Etoposide + cisplatin;Irinotecan + cisplatin
28 Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer Completed NCT00363415 Phase 3 pemetrexed;etoposide;carboplatin
29 Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer Completed NCT00658580 Phase 3 Cisplatin + etoposide;Epirubicin + ifosfamide + etoposide
30 Radiation Therapy Plus Combination Chemotherapy In Treating Patients With Limited Stage Small Cell Lung Cancer Completed NCT00003364 Phase 3 cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
31 Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer Completed NCT00003299 Phase 3 cisplatin;etoposide;paclitaxel
32 Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer Completed NCT00006352 Phase 3
33 Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer in Complete Remission Completed NCT00005062 Phase 3
34 Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer Completed NCT00061919 Phase 3 Carboplatin, etoposide & thalidomide;Carboplatin, etoposide & placebo
35 Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer Completed NCT00006349 Phase 3 donepezil hydrochloride
36 S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer Completed NCT00045162 Phase 3 cisplatin;etoposide;irinotecan hydrochloride
37 Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer Completed NCT00003279 Phase 3
38 Radiation Therapy to Prevent Brain Metastases in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer Completed NCT00016211 Phase 3
39 Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer Completed NCT00002822 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
40 Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer Completed NCT00003917 Phase 3 topotecan hydrochloride
41 A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC Completed NCT00144989 Phase 3 Etoposide and cisplatin after chemoradiotherapy;Irinotecan and cisplatin after chemoradiotherapy
42 Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer Completed NCT00320359 Phase 3 Intravenous topotecan/cisplatin;Intravenous etoposide/cisplatin
43 Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG Completed NCT00037713 Phase 3
44 A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer Completed NCT00349492 Phase 3 IP
45 Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer Completed NCT00041015 Phase 3 cisplatin;etoposide;topotecan hydrochloride
46 Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer Completed NCT00433498 Phase 3 carboplatin;cisplatin;etoposide phosphate;pravastatin sodium
47 Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer Completed NCT00660504 Phase 3 Amrubicin Hydrochloride;Etoposide-Cisplatin combined chemotherapy
48 Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide Completed NCT00290953 Phase 2, Phase 3 SR48692
49 Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer Completed NCT00276276 Phase 3 topotecan
50 National Lung Screening Trial (NLST) Screening Completed NCT00047385 Phase 3

Search NIH Clinical Center for Small Cell Carcinoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Small Cell Carcinoma

Anatomical Context for Small Cell Carcinoma

MalaCards organs/tissues related to Small Cell Carcinoma:

41
Lung, Brain, Prostate, Ovary, Cervix, Bone, Kidney

Publications for Small Cell Carcinoma

Articles related to Small Cell Carcinoma:

(show top 50) (show all 987)
# Title Authors Year
1
Primary small cell carcinoma of the ureter: Case report and review of the literature. ( 29901633 )
2018
2
Primary Mammary Small Cell Carcinoma. ( 29866240 )
2018
3
Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience. ( 29843803 )
2018
4
Small cell carcinoma of the stomach: A report of two cases and a review of the literature. ( 29896397 )
2018
5
Advanced small cell carcinoma of the cervix - Successful treatment with concurrent etoposide and cisplatin chemotherapy and extended field radiation: A case report and discussion. ( 29255785 )
2018
6
The use of adaptive intensity-modulated radiotherapy in the treatment of small-cell carcinoma lung refractory to chemotherapy in a patient with preexisting interstitial lung disease. ( 29319036 )
2018
7
Ovarian Small Cell Carcinoma: A Rare Case Report and Review of Literature. ( 29731803 )
2018
8
Insulinoma-Associated Protein 1 Immunostain: A Diagnostic Tool for Pulmonary Small Cell Carcinoma in Cytology. ( 29936498 )
2018
9
Identification of Driver Mutations in Rare Cancers: The Role of SMARCA4 in Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT). ( 29423809 )
2018
10
Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate. ( 29885405 )
2018
11
Cytological features of small cell carcinoma of the ovary-hypercalcemic type/malignant ovarian rhabdoid tumor in ascitic fluid. ( 29446248 )
2018
12
Successful treatment of a stage IIIC small-cell carcinoma of the ovary hypercalcemic subtype using multi-modality therapeutic approach. ( 29910829 )
2018
13
Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. ( 29365144 )
2018
14
Surgery for limited-stage primary small cell carcinoma of the esophagus: is it feasible and for whom is it indicated? ( 29849202 )
2018
15
Comments on "Treatment Strategies and Prognostic Factors of Limited-Stage Primary Small Cell Carcinoma of the Esophagus". ( 29425616 )
2018
16
Primary ovarian small cell carcinoma of pulmonary type with coexisting endometrial carcinoma in a breast cancer patient receiving tamoxifen: A case report and literature review. ( 29879027 )
2018
17
Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report. ( 29928211 )
2018
18
Primary Gastric Small Cell Carcinoma: A Case Identified as a Large Subepithelial Tumor from Invisible State in 6 Months. ( 29976037 )
2018
19
Small cell carcinoma of the urinary bladder: a Clinicopathologic and Immunohistochemical analysis of 81 cases. ( 29763719 )
2018
20
Intravesical recurrence after bladder sparing treatment of small cell carcinoma of the bladder: Characteristics, treatment, and outcome. ( 29580697 )
2018
21
Response to "Comments on Treatment Strategies and Prognostic Factors of Limited-Stage Primary Small Cell Carcinoma of the Esophagus". ( 29425617 )
2018
22
Tonsillar Small Cell Carcinoma: Potential Contribution of Human Papillomavirus. ( 29686221 )
2018
23
Nomograms to Predict Individual Prognosis of Patients with Primary Small Cell Carcinoma of the Bladder. ( 29675096 )
2018
24
Lambert-Eaton Myasthenic Syndrome Associated with Synchronous Double Cancer: A Combination of Small Cell Carcinoma of the Cervix and Breast Carcinoma. ( 29526952 )
2018
25
Combined small cell carcinoma with giant cell carcinoma component of the lung: A case successfully diagnosed by computed tomography-guided fine-needle aspiration cytology. ( 29399198 )
2018
26
Primary small cell carcinoma of the larynx. Survival time of 47 months. Case report. ( 29946458 )
2018
27
Extrapulmonary small cell carcinoma: an unfortunate case of metastatic disease. ( 29309906 )
2018
28
Concomitant small cell carcinoma and adenocarcinoma of the gallbladder: a case report. ( 29923489 )
2018
29
Dual Paraneoplastic Endocrine Syndromes Heralding Onset of Extrapulmonary Small Cell Carcinoma: A Case Report and Narrative Review. ( 29755405 )
2018
30
The genomic landscape of small cell carcinoma of the esophagus. ( 29728688 )
2018
31
Evaluating Treatment Patterns for Small Cell Carcinoma of the Colon Using the National Cancer Database (NCDB). ( 29354876 )
2018
32
Cervical small cell carcinoma frequently presented in multiple high risk HPV infection and often associated with other type of epithelial tumors. ( 29788963 )
2018
33
Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multi-kinase inhibition. ( 29440177 )
2018
34
Whole-Exome Sequencing of Sinonasal Small Cell Carcinoma Arising within a Papillary Schneiderian Carcinoma In Situ. ( 29734873 )
2018
35
Orbital metastatic small cell carcinoma of the pancreas with optic nerve compression. ( 29426454 )
2018
36
Molecular mechanisms of pathological tumor transformation and their clinical implications: predictors of pulmonary adenocarcinoma transformation into small cell carcinoma. ( 29268318 )
2017
37
A Long Survival Woman with Primary Small-Cell Carcinoma of the Gallbladder: Role of Chemotherapy Maintenance. ( 28744415 )
2017
38
Small Cell Carcinoma Mimicking Acute Leukemia. ( 28794375 )
2017
39
A case of resistance to tyrosine kinase inhibitor therapy: small cell carcinoma transformation concomitant with plasma-genotyped T790M positivity. ( 28723866 )
2017
40
SOX2 and Rb1 in esophageal small-cell carcinoma: their possible involvement in pathogenesis. ( 28106103 )
2017
41
Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: <i>In Vitro</i> and <i>In Vivo</i> Preclinical Models. ( 28292935 )
2017
42
Association of Li-Fraumeni Syndrome With Small Cell Carcinoma of the Ovary, Hypercalcemic Type and Concurrent Pleomorphic Liposarcoma of the Cervix. ( 28177947 )
2017
43
Sarcomatoid carcinoma associated with small cell carcinoma of the urinary bladder: a series of 28 cases. ( 28827101 )
2017
44
Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type. ( 29102090 )
2017
45
An investigation into the potential role of brain angiogenesis inhibitor protein 3 (BAI3) in the tumorigenesis of small-cell carcinoma: a review of the surrounding literature. ( 28537194 )
2017
46
Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Clinical and Imaging Review. ( 28943050 )
2017
47
Primary gastric small cell carcinoma. ( 28363459 )
2017
48
Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report. ( 28061471 )
2017
49
Therapeutic strategies and genetic profile comparisons in small cell carcinoma and large cell neuroendocrine carcinoma of the lung using next-generation sequencing. ( 29312580 )
2017
50
Re: Advanced Small Cell Carcinoma of the Bladder: Clinical Characteristics, Treatment Patterns and Outcomes in 960 Patients and Comparison with Urothelial Carcinoma. ( 28505896 )
2017

Variations for Small Cell Carcinoma

Expression for Small Cell Carcinoma

Search GEO for disease gene expression data for Small Cell Carcinoma.

Pathways for Small Cell Carcinoma

Pathways related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.57 EGFR KIT PTEN SMARCA4 TP53
2
Show member pathways
12.53 EGFR KIT PDGFRA PTEN TP53
3 12.52 EGFR KIT KLK3 PDGFRA PTEN TP53
4
Show member pathways
12.44 EGFR KIT KLK3 PDGFRA PTEN TMPRSS2
5 12.34 CALCA ENO2 NCAM1 NKX2-1 SYP
6
Show member pathways
12.33 EGFR PDGFRA PTEN TP53
7 11.98 EGFR PDGFRA PTEN TP53
8 11.92 EGFR PTEN SMARCA4 TP53
9 11.79 EGFR PTEN SMARCA4 TP53
10 11.69 EGFR KLK3 PTEN
11 11.63 KIT NCAM1 PTPRC
12 11.6 EGFR PDGFRA PTEN TP53
13 11.58 KIT NCAM1 PTPRC
14 11.38 KIT NCAM1 PDGFRA
15 11.34 EGFR PDGFRA TP53
16 11.25 ASCL1 NCAM1 PDGFRA SMARCA4 SYP
17 10.83 EGFR KIT PDGFRA PTEN TP53

GO Terms for Small Cell Carcinoma

Cellular components related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.26 KIT NCAM1 PDGFRA PTPRC
2 protein-containing complex GO:0032991 9.02 EGFR KLK3 PDGFRA SMARCA4 TP53

Biological processes related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription, DNA-templated GO:0045892 9.88 ASCL1 CALCA NKX2-1 SMARCA4 TP53
2 MAPK cascade GO:0000165 9.83 EGFR KIT NCAM1 PDGFRA
3 lung development GO:0030324 9.72 EGFR NKX2-1 PDGFRA
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.71 EGFR KIT PDGFRA PTEN
5 mast cell degranulation GO:0043303 9.56 CHGA KIT
6 positive regulation of cAMP metabolic process GO:0030816 9.54 CALCA CHGA
7 cerebral cortex cell migration GO:0021795 9.51 EGFR NKX2-1
8 positive regulation of kinase activity GO:0033674 9.5 EGFR KIT PDGFRA
9 tongue development GO:0043586 9.49 EGFR KIT
10 Leydig cell differentiation GO:0033327 9.46 NKX2-1 PDGFRA
11 forebrain neuron differentiation GO:0021879 9.43 ASCL1 NKX2-1
12 negative regulation of apoptotic process GO:0043066 9.43 ASCL1 EGFR KIT PDGFRA PTEN TP53
13 positive regulation of phospholipase C activity GO:0010863 9.37 KIT PDGFRA
14 mast cell chemotaxis GO:0002551 9.26 CHGA KIT
15 cerebral cortex GABAergic interneuron differentiation GO:0021892 9.16 ASCL1 NKX2-1
16 mast cell cytokine production GO:0032762 8.62 CHGA KIT

Molecular functions related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MAP kinase kinase kinase activity GO:0004709 9.54 EGFR KIT PDGFRA
2 mitogen-activated protein kinase kinase binding GO:0031434 9.43 EGFR KIT PDGFRA
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.33 EGFR KIT PDGFRA
4 obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.32 EGFR KIT
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 EGFR KIT PDGFRA
6 Ras guanyl-nucleotide exchange factor activity GO:0005088 8.92 EGFR KIT NCAM1 PDGFRA
7 protein binding GO:0005515 10.31 ASCL1 CALCA EGFR ENO2 KIT KLK3

Sources for Small Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....